PL368503A1 - Preparat galenowy do wstrzyknięć do stosowania w diagnostyce lub terapii fotodynamicznej oraz sposób wytwarzania go - Google Patents

Preparat galenowy do wstrzyknięć do stosowania w diagnostyce lub terapii fotodynamicznej oraz sposób wytwarzania go

Info

Publication number
PL368503A1
PL368503A1 PL02368503A PL36850302A PL368503A1 PL 368503 A1 PL368503 A1 PL 368503A1 PL 02368503 A PL02368503 A PL 02368503A PL 36850302 A PL36850302 A PL 36850302A PL 368503 A1 PL368503 A1 PL 368503A1
Authority
PL
Poland
Prior art keywords
photodynamic therapy
photosensitizer
diagnosis
preparing same
galenic formulation
Prior art date
Application number
PL02368503A
Other languages
English (en)
Inventor
Pierre-Herve Brun
Alain Prudhomme
Jean-Luc Barnoux
Original Assignee
Steba Biotech N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Steba Biotech N.V. filed Critical Steba Biotech N.V.
Publication of PL368503A1 publication Critical patent/PL368503A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
PL02368503A 2001-07-17 2002-07-05 Preparat galenowy do wstrzyknięć do stosowania w diagnostyce lub terapii fotodynamicznej oraz sposób wytwarzania go PL368503A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01810708A EP1277470A1 (fr) 2001-07-17 2001-07-17 Formulation galénique injectable pour utilisation dans un diagnostic ou une thérapie photodynamique et son procédé de préparation

Publications (1)

Publication Number Publication Date
PL368503A1 true PL368503A1 (pl) 2005-04-04

Family

ID=8184036

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02368503A PL368503A1 (pl) 2001-07-17 2002-07-05 Preparat galenowy do wstrzyknięć do stosowania w diagnostyce lub terapii fotodynamicznej oraz sposób wytwarzania go

Country Status (20)

Country Link
US (1) US20040147500A1 (pl)
EP (2) EP1277470A1 (pl)
JP (1) JP2004537562A (pl)
CN (1) CN1303999C (pl)
AT (1) ATE372769T1 (pl)
BR (1) BR0211173A (pl)
CA (1) CA2454150A1 (pl)
DE (1) DE60222421T2 (pl)
DK (1) DK1406616T3 (pl)
ES (1) ES2292781T3 (pl)
HU (1) HUP0400754A3 (pl)
IL (1) IL159620A0 (pl)
MX (1) MXPA04000042A (pl)
NO (1) NO20040216L (pl)
NZ (1) NZ530634A (pl)
PL (1) PL368503A1 (pl)
PT (1) PT1406616E (pl)
RU (1) RU2278665C2 (pl)
WO (1) WO2003009842A1 (pl)
ZA (1) ZA200400328B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825153B2 (en) * 2004-08-16 2010-11-02 Ceramoptec Industries, Inc. Photosensitizer formulations and their use
KR100866728B1 (ko) * 2004-11-12 2008-11-03 주식회사종근당 타크로리무스를 함유하는 주사제
EP2008665A1 (fr) * 2007-06-25 2008-12-31 Steba Biotech N.V. Formulation injectable pour thérapie photodynamique
RU2565766C1 (ru) * 2014-11-17 2015-10-20 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии и регенеративной медицины имени Е.Л. Гольдберга" 4-(3,4-дибромтиофенкарбонил)-2,6,8,12-тетраацетил-2,4,6,8,10,12-гексаазатетрацикло[5,5,0,03,11,05,9]додекан в качестве анальгетического средства и способ его получения
PT3225112T (pt) * 2016-04-01 2021-09-16 Trioptotec Gmbh Dispersão de fotossensibilizador e utilização da mesma
CN108670950B (zh) * 2018-06-29 2020-10-02 深圳海王医药科技研究院有限公司 一种不含有机溶剂的虎杖苷药物组合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2963178B2 (ja) * 1990-09-27 1999-10-12 株式会社エス・エル・ティ・ジャパン 水溶性フェオホーバイドａの製造方法
US5654423A (en) * 1990-11-21 1997-08-05 Regents Of The University Of California Boronated metalloporphyrine and therapeutic methods
JPH08505054A (ja) * 1992-12-23 1996-06-04 アイオア ステート ユニバーシティー リサーチ ファンデーション インコーポレーテッド 分子フラッシュ
US6147195A (en) * 1993-07-26 2000-11-14 Yeda Research And Development Co., Ltd. Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US5616342A (en) * 1995-04-11 1997-04-01 Pdt, Inc. Emulsioin suitable for administering a poorly water-soluble photosensitizing compound and use thereof
IL116126A0 (en) * 1995-11-24 1996-01-31 Yeda Res & Dev Process for the preparation of bacteriochlorophyllis some novel compounds of this type and pharmaceutical compositions comprising them
ES2277454T3 (es) * 1998-12-09 2007-07-01 Yeda Research And Development Co. Ltd. Derivados de bacterioclorofila sustituidos con paladio y uso de los mismos.

Also Published As

Publication number Publication date
PT1406616E (pt) 2007-12-20
HUP0400754A3 (en) 2005-11-28
EP1277470A1 (fr) 2003-01-22
DK1406616T3 (da) 2008-01-21
EP1406616B1 (fr) 2007-09-12
WO2003009842A8 (fr) 2004-04-01
BR0211173A (pt) 2004-08-10
EP1406616A1 (fr) 2004-04-14
CN1529594A (zh) 2004-09-15
NO20040216L (no) 2004-03-17
JP2004537562A (ja) 2004-12-16
NZ530634A (en) 2006-11-30
MXPA04000042A (es) 2005-08-16
ZA200400328B (en) 2004-09-13
CA2454150A1 (fr) 2003-02-06
CN1303999C (zh) 2007-03-14
ATE372769T1 (de) 2007-09-15
RU2004104469A (ru) 2005-04-20
DE60222421T2 (de) 2008-06-05
US20040147500A1 (en) 2004-07-29
RU2278665C2 (ru) 2006-06-27
HUP0400754A2 (hu) 2004-07-28
DE60222421D1 (de) 2007-10-25
IL159620A0 (en) 2004-06-01
WO2003009842A1 (fr) 2003-02-06
ES2292781T3 (es) 2008-03-16

Similar Documents

Publication Publication Date Title
EP1158959A4 (en) COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF HYDROPHOBIC THERAPEUTIC AGENTS
JP4804431B2 (ja) 長時間作用オキシテトラサイクリン組成物
CA2117651A1 (en) Itraconazole and saperconazole stereoisomers
DE60023465D1 (de) Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser
ZA937194B (en) 3,8-substituted deuteroporphyrin derivatives, pharmaceutical agents containing them and process for their production
WO2001094345A3 (en) Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
IL159620A0 (en) Injectable galenic formulation for use in a diagnosis or a photodynamic therapy and method for preparing same
HUP0202749A2 (hu) Levoszimendánt tartalmazó oldat formájú gyógyszerkészítmény
GR3025742T3 (en) New pyrazine derivatives, their preparation and their use.
GR3025207T3 (en) 2-Formylpyridine thiosemicarbazone derivatives, their preparation and their use as antitumor agents
CA2090911A1 (en) Aqueous pharmaceutical formulations of sodium cromoglycate
CA2412594A1 (en) Pyrazino[1',2':1,6]pyrido[3-4-5] indole derivatives
WO2003026570A3 (en) Reduced toxicity cisplatin formulations and methods for using the same
US5814635A (en) Concentrated injection solution of alkali metal salts of reduced folates
HUT46214A (en) Process for producing medical preparation suitable for treatment of peptic ulcer
CA2244085A1 (en) Therapeutic anti-asthma agents containing selenium compounds
AU2415699A (en) 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid
WO2003013380A3 (en) Multi-part dental bleaching systems and method for bleaching teeth using such systems
JP2822049B2 (ja) 水性製剤組成物
HUP0301334A2 (hu) Szubsztituált akriloil-disztamicin-származékokat és taxánokat és/vagy antimetabolitokat tartalmazó kombinált tumorellenes kompozíciók
JPS62265220A (ja) １，４−ジヒドロキシ−５，８−ビス〔２−（２−ヒドロキシエチルアミノ）−エチルアミノ〕アントラキノン二塩酸塩の安定な注射用医薬配合物
IE50512B1 (en) Pharmaceutical injectable composition and two-pack container for said composition
WO2002078605A3 (en) Premixed amiodarone parenteral solution and method for making the same
HUT75124A (en) Use of bicyclolactam derivatives for producing pharmaceutical compositions having anxiolytic activity
ES2100768T3 (es) Agente activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.